{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:41:43Z","timestamp":1794847303514,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01521-6","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:03:15Z","timestamp":1760691795000},"page":"1311-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Engineering a macromolecular JAK inhibitor for treating acute inflammation and endotoxaemia"],"prefix":"10.1038","volume":"10","author":[{"given":"Min","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-2947","authenticated-orcid":false,"given":"Jianxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1521_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","volume":"20","author":"MM Lamers","year":"2022","unstructured":"Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270\u2013284 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"1521_CR3","first-page":"56","volume":"9","author":"D Liu","year":"2022","unstructured":"Liu, D. et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil. Med. Res. 9, 56 (2022).","journal-title":"Mil. Med. Res."},{"key":"1521_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.kint.2019.05.026","volume":"96","author":"S Peerapornratana","year":"2019","unstructured":"Peerapornratana, S., Manrique-Caballero, C. L., G\u00f3mez, H. & Kellum, J. A. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 96, 1083\u20131099 (2019).","journal-title":"Kidney Int."},{"key":"1521_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","volume":"7","author":"P Kong","year":"2022","unstructured":"Kong, P. et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct. Target. Ther. 7, 131 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1521_CR6","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/all.15473","volume":"77","author":"G Varricchi","year":"2022","unstructured":"Varricchi, G. et al. Biologics and airway remodeling in severe asthma. Allergy 77, 3538\u20133552 (2022).","journal-title":"Allergy"},{"key":"1521_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1521_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1126\/science.1230720","volume":"339","author":"I Tabas","year":"2013","unstructured":"Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166\u2013172 (2013).","journal-title":"Science"},{"key":"1521_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1053\/j.gastro.2017.10.049","volume":"154","author":"I Bjarnason","year":"2018","unstructured":"Bjarnason, I. et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154, 500\u2013514 (2018).","journal-title":"Gastroenterology"},{"key":"1521_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Prim. 5, 58 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1521_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2215\/CJN.11290821","volume":"17","author":"MA Perazella","year":"2022","unstructured":"Perazella, M. A. & Rosner, M. H. Drug-induced acute kidney injury. Clin. J. Am. Soc. Nephrol. 17, 1220\u20131233 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1521_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tips.2017.05.008","volume":"38","author":"T Grosser","year":"2017","unstructured":"Grosser, T., Ricciotti, E. & FitzGerald, G. A. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol. Sci. 38, 733\u2013748 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong, P. & McCloskey, E. V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat. Rev. Endocrinol. 16, 437\u2013447 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li, J. X. & Cummins, C. L. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat. Rev. Endocrinol. 18, 540\u2013557 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","volume":"140","author":"CA Dinarello","year":"2010","unstructured":"Dinarello, C. A. Anti-inflammatory agents: present and future. Cell 140, 935\u2013950 (2010).","journal-title":"Cell"},{"key":"1521_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle, G. G. & Koppelman, G. H. Biologic therapies for severe asthma. N. Engl. J. Med. 386, 157\u2013171 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1521_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1521_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1521_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/17474124.2018.1530983","volume":"12","author":"ZA Borman","year":"2018","unstructured":"Borman, Z. A., Cote-Daigneault, J. & Colombel, J. F. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev. Gastroent. Hepatol. 12, 1101\u20131108 (2018).","journal-title":"Expert Rev. Gastroent. Hepatol."},{"key":"1521_CR20","first-page":"461","volume":"25","author":"I Khilfeh","year":"2019","unstructured":"Khilfeh, I. et al. Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study. J. Manag. Care Spec. Pharm. 25, 461\u2013467 (2019).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1521_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756283X17750355","volume":"11","author":"S Vermeire","year":"2018","unstructured":"Vermeire, S., Gils, A., Accossato, P., Lula, S. & Marren, A. Immunogenicity of biologics in inflammatory bowel disease. Therap. Adv. Gastroenterol. 11, 1\u201313 (2018).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"1521_CR22","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1021\/acs.molpharmaceut.8b00433","volume":"15","author":"X Wei","year":"2018","unstructured":"Wei, X. et al. Development of a Janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis. Mol. Pharm. 15, 3456\u20133467 (2018).","journal-title":"Mol. Pharm."},{"key":"1521_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11095-019-2587-6","volume":"36","author":"G Zhao","year":"2019","unstructured":"Zhao, G. et al. A macromolecular janus kinase (jak) inhibitor prodrug effectively ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Pharm. Res. 36, 64 (2019).","journal-title":"Pharm. Res."},{"key":"1521_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","volume":"19","author":"T N\u00e9meth","year":"2020","unstructured":"N\u00e9meth, T., Sperandio, M. & M\u00f3csai, A. Neutrophils as emerging therapeutic targets. Nat. Rev. Drug Discov. 19, 253\u2013275 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1521_CR25","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","volume":"236","author":"S Toldo","year":"2022","unstructured":"Toldo, S. et al. Targeting the nlrp3 inflammasome in cardiovascular diseases. Pharmacol. Ther. 236, 108053 (2022).","journal-title":"Pharmacol. Ther."},{"key":"1521_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd.2016.39","volume":"15","author":"JN Fullerton","year":"2016","unstructured":"Fullerton, J. N. & Gilroy, D. W. Resolution of inflammation: a new therapeutic frontier. Nat. Rev. Drug Discov. 15, 551\u2013567 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1521_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","volume":"21","author":"P Mehrotra","year":"2022","unstructured":"Mehrotra, P. & Ravichandran, K. S. Drugging the efferocytosis process: concepts and opportunities. Nat. Rev. Drug Discov. 21, 601\u2013620 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1521_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41578-022-00426-z","volume":"7","author":"ZX Tu","year":"2022","unstructured":"Tu, Z. X. et al. Design of therapeutic biomaterials to control inflammation. Nat. Rev. Mater. 7, 557\u2013574 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"1521_CR29","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1080\/10408398.2022.2025535","volume":"63","author":"D Yuan","year":"2023","unstructured":"Yuan, D., Li, C., Huang, Q., Fu, X. & Dong, H. Current advances in the anti-inflammatory effects and mechanisms of natural polysaccharides. Crit. Rev. Food Sci. Nutr. 63, 5890\u20135910 (2023).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"1521_CR30","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1021\/acsnano.4c00120","volume":"18","author":"K Hu","year":"2024","unstructured":"Hu, K. et al. Pathogenesis-guided rational engineering of nanotherapies for the targeted treatment of abdominal aortic aneurysm by inhibiting neutrophilic inflammation. ACS Nano 18, 6650\u20136672 (2024).","journal-title":"ACS Nano"},{"key":"1521_CR31","doi-asserted-by":"publisher","first-page":"2100548","DOI":"10.1002\/adfm.202100548","volume":"31","author":"A Nishiguchi","year":"2021","unstructured":"Nishiguchi, A. & Taguchi, T. Oligoethyleneimine-conjugated hyaluronic acid modulates inflammatory responses and enhances therapeutic efficacy for ulcerative colitis. Adv. Funct. Mater. 31, 2100548 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"1521_CR32","doi-asserted-by":"publisher","first-page":"1800781","DOI":"10.1002\/advs.201800781","volume":"5","author":"L Li","year":"2018","unstructured":"Li, L. et al. A broad-spectrum ROS-eliminating material for prevention of inflammation and drug-induced organ toxicity. Adv. Sci. 5, 1800781 (2018).","journal-title":"Adv. Sci."},{"key":"1521_CR33","first-page":"12","volume":"28","author":"J Cai","year":"2023","unstructured":"Cai, J. et al. Intrinsically bioactive and biomimetic nanoparticle-derived therapies alleviate asthma by regulating multiple pathological cells. Bioact. Mater. 28, 12\u201326 (2023).","journal-title":"Bioact. Mater."},{"key":"1521_CR34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1021\/acscentsci.0c01669","volume":"7","author":"CS Delaveris","year":"2021","unstructured":"Delaveris, C. S. et al. Synthetic Siglec-9 agonists inhibit neutrophil activation associated with COVID-19. ACS Cent. Sci. 7, 650\u2013657 (2021).","journal-title":"ACS Cent. Sci."},{"key":"1521_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1021\/acscentsci.9b01199","volume":"6","author":"S Ramadan","year":"2020","unstructured":"Ramadan, S. et al. Chemical synthesis and anti-inflammatory activity of bikunin associated chondroitin sulfate 24-mer. ACS Cent. Sci. 6, 913\u2013920 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1521_CR36","doi-asserted-by":"publisher","first-page":"19679","DOI":"10.1073\/pnas.1003103107","volume":"107","author":"J Dernedde","year":"2010","unstructured":"Dernedde, J. et al. Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proc. Natl Acad. Sci. USA 107, 19679\u201319684 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1521_CR37","doi-asserted-by":"publisher","first-page":"E7660","DOI":"10.1073\/pnas.1704858114","volume":"114","author":"I Posadas","year":"2017","unstructured":"Posadas, I. et al. Neutral high-generation phosphorus dendrimers inhibit macrophage-mediated inflammatory response in vitro and in vivo. Proc. Natl Acad. Sci. USA 114, E7660\u2013e7669 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1521_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018627118","volume":"118","author":"KM Hainline","year":"2021","unstructured":"Hainline, K. M. et al. Modular complement assemblies for mitigating inflammatory conditions. Proc. Natl Acad. Sci. USA 118, e2018627118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1521_CR39","doi-asserted-by":"publisher","first-page":"2301918","DOI":"10.1002\/adfm.202301918","volume":"33","author":"HY Chen","year":"2023","unstructured":"Chen, H. Y. et al. Rational engineering of a mitochondrial-mimetic therapy for targeted treatment of dilated cardiomyopathy by precisely regulating mitochondrial homeostasis. Adv. Funct. Mater. 33, 2301918 (2023).","journal-title":"Adv. Funct. Mater."},{"key":"1521_CR40","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2217\/nnm.15.87","volume":"10","author":"A Eguchi","year":"2015","unstructured":"Eguchi, A. et al. Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis. Nanomedicine 10, 2697\u20132708 (2015).","journal-title":"Nanomedicine"},{"key":"1521_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41563-019-0462-9","volume":"19","author":"Y Lee","year":"2020","unstructured":"Lee, Y. et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 19, 118\u2013126 (2020).","journal-title":"Nat. Mater."},{"key":"1521_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.04.011","volume":"133","author":"JY Kim","year":"2017","unstructured":"Kim, J. Y. et al. Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury. Biomaterials 133, 1\u201310 (2017).","journal-title":"Biomaterials"},{"key":"1521_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2023.101957","volume":"52","author":"L Li","year":"2023","unstructured":"Li, L. et al. Site-specific inhibition of neutrophilic inflammation by low-dose nanotherapy for immunoregulatory treatment of asthma. Nano Today 52, 101957 (2023).","journal-title":"Nano Today"},{"key":"1521_CR44","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1021\/acsnano.8b02037","volume":"12","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano 12, 8943\u20138960 (2018).","journal-title":"ACS Nano"},{"key":"1521_CR45","doi-asserted-by":"publisher","first-page":"2209466","DOI":"10.1002\/adfm.202209466","volume":"33","author":"G Li","year":"2023","unstructured":"Li, G. et al. Stem cell-niche engineering via multifunctional hydrogel potentiates stem cell therapies for inflammatory bone loss. Adv. Funct. Mater. 33, 2209466 (2023).","journal-title":"Adv. Funct. Mater."},{"key":"1521_CR46","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.1073\/pnas.1607011113","volume":"113","author":"EK Holl","year":"2016","unstructured":"Holl, E. K. et al. Scavenging nucleic acid debris to combat autoimmunity and infectious disease. Proc. Natl Acad. Sci. USA 113, 9728\u20139733 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1521_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303385120","volume":"120","author":"HF Zhu","year":"2023","unstructured":"Zhu, H. F., Kong, B., Che, J. Y., Zhao, Y. J. & Sun, L. Y. Bioinspired nanogels as cell-free DNA trapping and scavenging organelles for rheumatoid arthritis treatment. Proc. Natl Acad. Sci. USA 120, e2303385120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1521_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.mattod.2017.09.003","volume":"20","author":"J Guo","year":"2017","unstructured":"Guo, J. et al. A myeloperoxidase-responsive and biodegradable luminescent material for real-time imaging of inflammatory diseases. Mater. Today 20, 493\u2013500 (2017).","journal-title":"Mater. Today"},{"key":"1521_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nm.1886","volume":"15","author":"S Gross","year":"2009","unstructured":"Gross, S. et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat. Med. 15, 455\u2013461 (2009).","journal-title":"Nat. Med."},{"key":"1521_CR50","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.talanta.2006.12.045","volume":"72","author":"F Barni","year":"2007","unstructured":"Barni, F., Lewis, S. W., Berti, A., Miskelly, G. M. & Lago, G. Forensic application of the luminol reaction as a presumptive test for latent blood detection. Talanta 72, 896\u2013913 (2007).","journal-title":"Talanta"},{"key":"1521_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.scijus.2007.08.003","volume":"48","author":"T Larkin","year":"2008","unstructured":"Larkin, T. & Gannicliffe, C. Illuminating the health and safety of luminol. Sci. Justice 48, 71\u201375 (2008).","journal-title":"Sci. Justice"},{"key":"1521_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904607","volume":"31","author":"J Guo","year":"2019","unstructured":"Guo, J. et al. Cyclodextrin-derived intrinsically bioactive nanoparticles for treatment of acute and chronic inflammatory diseases. Adv. Mater. 31, e1904607 (2019).","journal-title":"Adv. Mater."},{"key":"1521_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.nantod.2010.10.006","volume":"5","author":"C Yang","year":"2010","unstructured":"Yang, C. et al. Supramolecular nanostructures designed for high cargo loading capacity and kinetic stability. Nano Today 5, 515\u2013523 (2010).","journal-title":"Nano Today"},{"key":"1521_CR54","first-page":"51","volume":"49","author":"NN Palei","year":"2024","unstructured":"Palei, N. N., Rajangam, J., Samineni, R., Dhar, A. K. & Balaji, A. Formulation and evaluation of mixed micelles containing quercetin for inhibiting intestinal metabolism of atorvastatin. FABAD J. Pharm. Sci. 49, 51\u201364 (2024).","journal-title":"FABAD J. Pharm. Sci."},{"key":"1521_CR55","first-page":"329","volume":"53","author":"Y Qi","year":"2025","unstructured":"Qi, Y. et al. Advanced nanotherapies for precision treatment of inflammatory lung diseases. Bioact. Mater. 53, 329\u2013365 (2025).","journal-title":"Bioact. Mater."},{"key":"1521_CR56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.addr.2020.07.010","volume":"157","author":"R Brusini","year":"2020","unstructured":"Brusini, R., Varna, M. & Couvreur, P. Advanced nanomedicines for the treatment of inflammatory diseases. Adv. Drug Deliv. Rev. 157, 161\u2013178 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1521_CR57","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.addr.2012.03.006","volume":"64","author":"F Yuan","year":"2012","unstructured":"Yuan, F., Quan, L. D., Cui, L., Goldring, S. R. & Wang, D. Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev. 64, 1205\u20131219 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1521_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb7422","volume":"6","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule. Sci. Adv. 6, eabb7422 (2020).","journal-title":"Sci. Adv."},{"key":"1521_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41423-020-00560-0","volume":"18","author":"K Liu","year":"2021","unstructured":"Liu, K., Wang, F. S. & Xu, R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell. Mol. Immunol. 18, 38\u201344 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1521_CR60","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.it.2024.02.003","volume":"45","author":"J Liu","year":"2024","unstructured":"Liu, J., Kang, R. & Tang, D. Lipopolysaccharide delivery systems in innate immunity. Trends Immunol. 45, 274\u2013287 (2024).","journal-title":"Trends Immunol."},{"key":"1521_CR61","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41422-020-0291-z","volume":"30","author":"EM P\u00e5lsson-McDermott","year":"2020","unstructured":"P\u00e5lsson-McDermott, E. M. & O\u2019Neill, L. A. J. Targeting immunometabolism as an anti-inflammatory strategy. Cell Res. 30, 300\u2013314 (2020).","journal-title":"Cell Res."},{"key":"1521_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz, M. & Kiladjian, J. J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35, 1\u201317 (2021).","journal-title":"Leukemia"},{"key":"1521_CR63","unstructured":"Holford, N. in Dose Finding in Drug Development (ed. Ting, N.) 73\u201388 (Springer, 2006)."},{"key":"1521_CR64","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1871523018666190514112048","volume":"19","author":"T Ahmed","year":"2020","unstructured":"Ahmed, T. et al. Evaluation of the anti-inflammatory activities of diclofenac sodium, prednisolone and atorvastatin in combination with ascorbic acid. Antiinflamm. Antiallergy Agents Med. Chem. 19, 291\u2013301 (2020).","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"1521_CR65","first-page":"430","volume":"14","author":"Z Zhai","year":"2022","unstructured":"Zhai, Z. et al. Dexamethasone-loaded ROS-responsive poly(thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury. Bioact. Mater. 14, 430\u2013442 (2022).","journal-title":"Bioact. Mater."},{"key":"1521_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00431-016-2830-7","volume":"176","author":"AE El-Mashad","year":"2017","unstructured":"El-Mashad, A. E., El-Mahdy, H., El Amrousy, D. & Elgendy, M. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. Eur. J. Pediatr. 176, 233\u2013240 (2017).","journal-title":"Eur. J. Pediatr."},{"key":"1521_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2018.02.028","volume":"118","author":"M Qian","year":"2018","unstructured":"Qian, M. et al. Pick1 deficiency exacerbates sepsis-associated acute lung injury and impairs glutathione synthesis via reduction of xct. Free Radic. Biol. Med. 118, 23\u201334 (2018).","journal-title":"Free Radic. Biol. Med."},{"key":"1521_CR68","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/pharmaceutics12111038","volume":"12","author":"HD Jhundoo","year":"2020","unstructured":"Jhundoo, H. D. et al. Anti-inflammatory activity of chitosan and 5-amino salicylic acid combinations in experimental colitis. Pharmaceutics 12, 1038 (2020).","journal-title":"Pharmaceutics"},{"key":"1521_CR69","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1126\/science.abi5200","volume":"374","author":"R Medzhitov","year":"2021","unstructured":"Medzhitov, R. The spectrum of inflammatory responses. Science 374, 1070\u20131075 (2021).","journal-title":"Science"},{"key":"1521_CR70","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2174\/0929867325666180327093502","volume":"26","author":"F Musumeci","year":"2019","unstructured":"Musumeci, F. et al. An update on jak inhibitors. Curr. Med. Chem. 26, 1806\u20131832 (2019).","journal-title":"Curr. Med. Chem."},{"key":"1521_CR71","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Evolving cognition of the jak-stat signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target. Ther. 8, 204 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1521_CR72","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo, S., Nakayamada, S. & Tanaka, Y. JAK inhibitors for rheumatoid arthritis. Expert. Opin. Investig. Drugs 32, 333\u2013344 (2023).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1521_CR73","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","volume":"83","author":"P N\u00fa\u00f1ez","year":"2023","unstructured":"N\u00fa\u00f1ez, P., Quera, R. & Yarur, A. J. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs 83, 299\u2013314 (2023).","journal-title":"Drugs"},{"key":"1521_CR74","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1521_CR75","unstructured":"Zhang, J. X. et al. Engineering a macromolecular JAK inhibitor for treating acute inflammation and endotoxemia. Genome Sequence Archive CRA028017. https:\/\/ngdc.cncb.ac.cn\/gsa\/browse\/CRA028017 (2025)."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01521-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:02:58Z","timestamp":1784239378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01521-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01521-6","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Z., K.H. and J.Z. are inventors in a pending patent filed by the China National Intellectual Property Administration (number 2025101169778, 24 January 2025) related to HPL-based therapies, but the rights belong to the Third Military Medical University and Yu-Yue Pathology Scientific Research Center. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}